On Oct. 17, Kenvue filed a response to the Citizen Petition, arguing against the need to add a pregnancy/autism risk warning ...

Kenvue has urged U.S. regulators to reject a request seeking autism warning label on its popular over-the-counter pain ...

格隆汇10月21日｜Kenvue敦促美国监管机构拒绝有公民请愿书要求泰诺加上自闭症关联的标签。Kenvue于本月17日提交给美国食品药物管理局 ...

Kenvue urged U.S. regulators to deny a request warning against Tylenol’s use during pregnancy, laying out the most detailed ...

Kenvue Inc. (NYSE: KVUE), spun out from Johnson & Johnson in 2023, is at a crossroads. As the world's largest pure-play ...

A potential legal headache for consumer healthcare giant Kenvue ( KVUE -13.50%) was causing pain for investors on Thursday.

智通财经APP获悉，强生(JNJ.US)首次在英国面临诉讼，指控其滑石粉产品致癌，而该公司在美国正应对数万起类似索赔。该诉讼于周二在英国高等法院提起，被告为强生及其子公司Kenvue的英国分公司Kenvue UK ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Kenvue Inc 股价触及52周低点，收盘价为15.46美元。这家市值达312亿美元的消费健康巨头目前为投资者提供了显著的5.1%股息收益率。根据 InvestingPro 分析，该股票似乎正在以低于其公允价值的价格交易。这标志着该公司在市场上经历了充满挑战的一年后出现了显著下滑。在过去12个月中，Kenvue的股票经历了大幅下跌，一年变化率为-27.27%。尽管价格承压，但该公司仍保持着58 ...

Investing.com - Canaccord Genuity 重申了对 Kenvue Inc (NYSE:KVUE) 的买入评级和 $26.00 的目标价，尽管存在英国滑石粉诉讼责任的担忧。根据 InvestingPro 数据显示，该目标价较当前水平有显著上涨空间，目前该股票提供高达5.88%的股息收益率。

Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded after a flurry of corporate earnings ...

Kenvue Inc. offers stable financials, robust 5% dividend yield, and trades at a significant discount to peers. Learn more ...